Profile data is unavailable for this security.
About the company
Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.
- Revenue in GBP (TTM)0.00
- Net income in GBP-8.41m
- Incorporated2004
- Employees30.00
- LocationSynairgen PLCSouthampton General Hosp, Tremona RoadSOUTHAMPTON SO16 6YDUnited KingdomGBR
- Phone+44 23 8051 2800Fax+44 23 8051 2800
- Websitehttps://www.synairgen.com/
More ▼
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| ValiRx Plc | 9.60k | -2.04m |
| BSF Enterprise PLC | 67.24k | -1.71m |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.72m |
| Synairgen plc | 0.00 | -8.41m |
| Oncimmune Holdings PLC | 1.21m | -3.19m |
| ImmuPharma PLC | 0.00 | -2.92m |
| Kanabo Group PLC | 895.00k | -7.99m |
| Genflow Biosciences PLC | 0.00 | -1.63m |
| Destiny Pharma PLC | 0.00 | -5.66m |
| Bivictrix Therapeutics PLC | 0.00 | -2.55m |
| Chill Brands Group PLC | 146.62k | -3.64m |
Data as of Jun 28 2024. Currency figures normalised to Synairgen PLC's reporting currency: UK Pound GBX
Institutional shareholders
28.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| TFG Asset Management UK LLPas of 26 Apr 2023 | 56.70m | 28.15% |
| Premier Fund Managers Ltd.as of 30 Apr 2023 | 0.00 | 0.00% |
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
